Stage IV AFP-producing gastric cancer responds to chemotherapy and immunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative; pMMR; elevated AFP

Metastatic Site: liver|peritoneum

Imaging showed a sustained partial response, his AFP level returned to normal, and he continued maintenance serplulimab at the latest follow-up.

PubMed CentralRead more →

Stage III Colorectal Adenocarcinoma: Meagan's Survivor Story

Patient Info: Meagan, Female, Under 40 | Stage III

In remission after surgery and 6 months of FOLFOX for high-risk Stage IIIC sigmoid colon adenocarcinoma, with ongoing 6-month scan monitoring and survivorship challenges including scanxiety and neuropathy.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Kalei's Patient Story

Patient Info: Kalei, Female | Stage IV

Metastatic Site: Lungs

Living with Stage IV rectal cancer after lung metastases were treated surgically; later imaging raised concern for possible recurrence in the lung and rectal area, but lymph-node biopsy was clear and further workup was ongoing.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Joe's Patient Story

Patient Info: Joe, Male | Stage IV

Biomarkers: Specific biomarkers not reported

Metastatic Site: Liver; lymph nodes; lungs

Stage IV colon cancer initially reached no evidence of disease after FOLFOX plus panitumumab, but later recurred in the liver and lymph nodes, progressed to the lungs, and did not respond to later FOLFOX rechallenge or FOLFIRI before he started an immunotherapy clinical trial.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Sydney's Patient Story

Patient Info: Sydney, Female | Stage IV

Metastatic Site: Liver; lungs

Sydney was living with Stage IV colorectal cancer involving the liver and lungs. After multiple lines of treatment, she had a new liver spot and was back on lower-dose FOLFIRI every other Tuesday with a 46-hour pump.

The Patient StoryRead more →

Stage IV gastric cancer with benign breast hemangioma during ramucirumab therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Gastric cancer: HER2 negative, PD-L1 TPS >=5%

Metastatic Site: peritoneum; preaortic lymph nodes; omentum

After initial response to FOLFOX/nivolumab and temporary benefit from paclitaxel/ramucirumab and FOLFIRI, the gastric cancer progressed to massive ascites. Trifluridine/tipiracil was attempted, but she died from rapid disease progression.

PubMed CentralRead more →

Teenage colorectal cancer: Stage III signet-ring adenocarcinoma and 10-year disease-free follow-up after FOLFOX

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: CDX2-positive; CK7-positive; AE1-AE3-positive; signet-ring cell adenocarcinoma histology

As of November 2025, she was disease-free 10 years after laparoscopic right hemicolectomy with clear margins and 6 months of adjuvant FOLFOX for T4N2Mx signet-ring colon adenocarcinoma.

PubMed CentralRead more →

Colon cancer patient with insulin autoimmune syndrome after FOLFOX, bevacizumab, and omeprazole

Patient Info: Anonymized, Male, 70+

Biomarkers: No cancer biomarkers reported. Insulin autoimmune syndrome followed chemotherapy/omeprazole exposure.

As of November 2025, the rare insulin autoimmune syndrome episode had improved after glucose supplementation and prednisone acetate, with blood glucose returning to the normal range during postoperative colon cancer treatment.

PubMed CentralRead more →

Metastatic Gastric Cancer Treatment Complicated by Recurrent Cytokine Release Syndrome

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: peritoneum, bone

She had a partial response after 6 cycles but later chose to stop chemotherapy because treatment toxicity and declining health were affecting quality of life.

PubMed CentralRead more →

Stage IV KRAS-mutant colorectal cancer with bilobar liver metastases: multimodality treatment and no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS-mutated; BRAF wild-type; mismatch repair proficient

Metastatic Site: liver

After second liver resection, follow-up MRI at 8 weeks showed continued response at the SABR site and no recurrent disease; she was receiving adjuvant capecitabine and remained well.

PubMed CentralRead more →

Stage III dMMR transverse colon cancer: colectomy and adjuvant FOLFOX with no recurrence on CT

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Loss of MLH1 and PMS2; BRAF mutation; MMR-deficient colorectal cancer

After colectomy and initiation of planned adjuvant FOLFOX, surveillance abdominal CT showed no recurrence or metastasis.

PubMed CentralRead more →

Stage IV sigmoid colon cancer: recurrence after FOLFOX, hepatectomy, and colectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Mismatch repair proficient; microsatellite stable; KRAS wild-type; BRAF wild-type; CEA 3.8 ng/mL at diagnosis

Metastatic Site: liver, lung

As of September 2025, metastatic sigmoid colon cancer had recurred in the lungs and remnant liver after initial FOLFOX, hepatectomy, and colectomy, requiring FOLFIRI plus cetuximab.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Heather's Patient Story

Patient Info: Heather Candrilli, Female, Under 40 | Stage IV

Metastatic Site: Liver

Heather had Stage IV colon cancer with liver-only metastases. Her scans improved and Signatera became negative, but she still had many liver lesions and was not considered resectable. As of September 2025, she remained on chemotherapy while pursuing living-donor liver transplant evaluation.

The Patient StoryRead more →

Stage III Colorectal Cancer: Nicole's Survivor Story

Patient Info: Nicole, Female, Under 40 | Stage III

Nicole completed surgery and 6 months of chemotherapy for Stage III sigmoid colon cancer. As of August 2025, she described good scans and bloodwork while managing survivorship issues, including lasting chemotherapy-related nerve damage.

The Patient StoryRead more →

Stage III Colorectal Cancer: Ian's Survivor Story

Patient Info: Ian, Male, Under 40 | Stage III

Ian had Stage III sigmoid colon cancer treated with robotic laparoscopic surgery and adjuvant FOLFOX-based chemotherapy. As of July 2025, he described negative ctDNA tests and clear scans, with his oncologist comfortable saying he had been NED since surgery on December 13, 2022.

The Patient StoryRead more →

Stage IIIC ascending colon adenocarcinoma with appendiceal goblet-cell/signet-ring features: no recurrence at 46 months

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: Colon tumor: MMR proteins retained, p53 positive, Ki-67 80%. Appendix lesion had neuroendocrine markers and Ki-67 10%.

At last follow-up on December 31, 2024, about 46 months after surgery, outside CT imaging and CEA testing showed no radiologic or biochemical evidence of tumor recurrence or metastasis.

PubMed CentralRead more →

Metastatic colorectal cancer during pregnancy: chemotherapy and liver metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Mismatch-repair deficient; KRAS ; BRAF not detected; CEA 38 ug/L; Lynch syndrome family history

Metastatic Site: liver, porta hepatis lymph nodes, retroperitoneal…

After initial response to FOLFOX, she developed bowel obstruction after moving closer to family and died during that admission after conservative management.

PubMed CentralRead more →

Stage 4 colorectal cancer: complete response with panitumumab and FOLFOX4

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: KRAS/NRAS/BRAF wild type; MSS/pMMR; HER2 not overexpressed. CEA and CA19-9 were elevated.

Metastatic Site: periaortic and pelvic lymph nodes; left ovary/adnexa

As of November 2024, she was alive and continuing second-line FOLFIRI with stable disease after prior complete remission on panitumumab plus FOLFOX4 and later progression with ovarian metastasis.

PubMed CentralRead more →

Metastatic colon cancer: soft-tissue and adrenal metastases responding to FOLFIRI plus bevacizumab

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: KRAS codon 146 mutation; BRAF wild type. CK20 and Ki-67 supported colorectal metastasis; CEA/CA19-9 were elevated.

Metastatic Site: lungs; left arm/biceps soft tissue; right…

As of May 2025, metastatic colon cancer involving soft tissue, muscle, lung history, and right adrenal gland had regressed after 12 months of FOLFIRI plus bevacizumab, and the patient was alive 1 year after chemotherapy completion.

PubMed CentralRead more →

Metastatic Colorectal Cancer With NRG1 Fusion Controlled for Years With Afatinib

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: MATN-NRG1 fusion; no KRAS alteration detected

Afatinib controlled her metastatic colorectal cancer for 136 weeks. After resection of the remaining target lesion in September 2022, she remained alive with no progression as of October 2024.

PubMed CentralRead more →

Michelle: Stage IV Colorectal Cancer

Patient Info: Michelle, Female, 40s | Stage IV

Metastatic Site: Ovary | Femoral nerve region

As of April 2025, Michelle described living as a Stage IV colorectal cancer survivor after FOLFOX, major surgery, 2.5 years with no evidence of disease, and a later PET-detected recurrence involving the femoral nerve region.

The Patient StoryRead more →

Stage III Colorectal Cancer: Edie's Survivor Story

Patient Info: Edie, Female, 50s | Stage III

After total neoadjuvant treatment, lower anterior resection, and ileostomy reversal, Edie reported clear scans/colonoscopies and described herself as a colon cancer survivor. As of February 2025, she remained in survivorship.

The Patient StoryRead more →

Stage IV HER2-Positive Colorectal Cancer: Emily's Patient Story

Patient Info: Emily King, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: lungs

Emily remained on active treatment for metastatic HER2-positive colon cancer, and her current Boston treatment had shrunk the cancer by 20% with fewer side effects.

The Patient StoryRead more →

How I Found Out I Had Stage 4 Colon Cancer!

Patient Info: Rachael Marie, Female, Under 40 | Stage IV

Metastatic Site: ovaries, liver

Rachael completed 12 cycles of FOLFOX/oxaliplatin; colonoscopy looked clear, liver lesions had shrunk, and no new lesions were reported, with further surgical planning pending.

The Patient StoryRead more →